Tenders Are Invited For Pharmaceutical Products - Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Clobetasol Exclusively In The Daring Form Foam, Atc D07ad01 For The Time 01.11.2025 - 31.10.2027

Pharmaceutical Products - Completion Of A Non -Exclusive Discount Agreement According To Section 130A (8) Sgb V For The Active Ingredient Clobetasol Exclusively In The Daring Form Foam, Atc D07ad01 For The Time 01.11.2025 - 31.10.2027. The Dak Health Assumes That This Procedure Does Not Fall Into The Scope Of The Antitrust Gever Law Due To A Lack Of Selection Decision And Thus The Possibility Of Discriminatory Access Of All Pharmaceutical Companies. Regardless Of This, It Automatically Ends With The Entry Into Force Of The Exclusive Contract To The Active Ingredient Clobetasol Exclusively In The Dosage Form Foam, Atc D07ad01, As A Result Of A Formal Award Procedure According To The Regulations Of The 4Th Part Of The Gwb With One Or More Contractual Partners. In Order To Meet The Diversity Of The Potential Contractual Partners Within The Framework Of The Approval Model, Every Pharmaceutical Company Will Be Enabled To Conclude A Framework Contract At Any Time And On The Same Conditions During The Contract Term. The Contract Documents Required For This Can Be Found On The Online Portal Www.Dtvp.De/Center On 5.1.11. Mentioned Link For Download. Requirements For The Conclusion Or The Later Accession To The Contracts That Have Been Entered For The First Time On 01.11.2025 Are The Complete And Timely Sending Of The Following Documents (Available For Download Under The Link Mentioned Under 5.1.11.) To The Following Department In Dak-Gesundheit: 1. Submission Of The Contract With Name Or Company Stamp By The Prospect At The Intended Body. 3. The Completed Systems 1 And 2 To The Contract. The Prospect Must Enter The Drugs For The Above -Mentioned Active Ingredient, Which Should Become Subject To The Contract. The Documents Must Be Submitted By Email At: [email protected] Dak-Gesundheit Department Of Medicines (0038 00) Nagelsweg 27-31 20097 Hamburg The Appendix 2 Is Expressly Sent To The E-Mail Address [email protected]. Contracts Within The Framework Of This Model And The Above-Mentioned Active Ingredient Will Be Concluded For The First Time With Effect On 01.11.2025 And Ends On October 31, 2027. Interestments Who Want To Become Contractual Partners Have To Submit The Documents To Be Submitted By Email Until 5. The Previous Month. The Offer Is To Be Submitted In Text Form As An Electronic Offer By Email At [email protected]. The Submission Of The Offer By Post Is Not Provided In This Procedure. Please Do Not Submit The Offer Via The German Award Portal. An Electronic Input Of The Complete Documents By Email To The Email Address [email protected] Is Sufficient For The Deadline. Later Joining Is Possible At Any Time. In Order To Be Able To Join The 1St Or 15Th Of The Following Month During The Term Of The Contract, The Above Documents, Regardless Of The Desired Accession, Must Be Available To The Dak Health Up To The 5Th Month. Here, Too, It Depends On The Timely Access By Email At The Dak-G. Example: The